[Special Stock] Newgislab Pharma, COVID-19 Resurgence... "30-50 Times More Effective Than Existing" Treatment Phase 2 Spotlighted↑

[Asia Economy Reporter Jang Hyowon] As the daily new cases worldwide approach 1 million due to the resurgence of COVID-19 variants, NewGene Lab Pharma is showing strong performance.

NewGene Lab Pharma's oral treatment is reported to be up to about 50 times more effective compared to Merck's 'Molnupiravir' and about twice as effective in intestinal cells compared to Pfizer's 'Paxlovid.'

As of 2:19 PM on the 18th, NewGene Lab Pharma is trading at 9,960 KRW, up 480 KRW (5.06%) from the previous trading day.

According to the media, the 'doubling' phenomenon, where new domestic cases have doubled compared to a week ago, has continued for over ten days, filling more than half of the semi-intensive care beds.

On the 17th (local time), according to The New York Times (NYT) based on Johns Hopkins University data, the daily average of new cases over the past week as of the 16th was 950,652. This is a 24% increase compared to two weeks ago. Compared to June 5th's 466,711 cases, it is more than double.

China's daily new COVID-19 infections also exceeded 500 again after about 50 days. According to NHK data, Japan also reported a record high of over 110,000 new cases.

Meanwhile, NewGene Lab Pharma's subsidiary, NewGene Therapeutics, is reportedly progressing smoothly with Phase 2 clinical trials of the oral COVID-19 treatment 'NewGen Nafamostat Tablets.'

This treatment is being developed through drug repurposing of 'Nafamostat,' originally known as a pancreatitis treatment, and is reported to have safety and efficacy against variant viruses.

According to research results from Goethe University Frankfurt in Germany and the University of Kent in the UK, Nafamostat showed up to about 50 times greater effectiveness against Omicron and Delta variants compared to Merck's oral treatment 'Molnupiravir,' and about twice the effect in intestinal cells compared to Pfizer's oral treatment 'Paxlovid,' highlighting it as a promising candidate for COVID-19 variant treatment.

Oral treatments can be easily taken even during self-quarantine and are effective in preventing severe cases and reducing hospital admission rates.

This content was produced with the assistance of AI translation services.